申请人:Zeneca Limited
公开号:US05478842A1
公开(公告)日:1995-12-26
The invention concerns ether derivatives of the formula I Q.sup.1 --X--Ar--Q.sup.2 I wherein Q.sup.1 is an optionally substituted 9-, 10- or 11-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur; X is oxy, thio, sulphinyl or sulphonyl; Ar is optionally substituted phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl, thiazolediyl, oxazoiediyl, thiadiazoiediyl or oxadiazolediyl; and Q.sup.2 is selected from the groups of the formulae II and III: ##STR1## wherein R.sup.1 is hydrogen, (2-5C)alkanoyl or optionally substituted benzoyl; R.sup.2 is (1-4C)alkyl; and R.sup.3 is hydrogen or (1-4C)alkyl; or R.sup.2 and R.sup.3 are linked to form a methylene, vinylene, ethylene or trimethylene group; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.
本发明涉及公式I的醚衍生物 Q.sup.1 --X--Ar--Q.sup.2 I,其中Q.sup.1是可选地取代的含有一个或两个氮杂原子的9-、10-或11-成环杂环部分,并且可选地含有从氮、氧和硫中选择的另外一种杂原子;X是氧乙基、硫乙基、亚磺酰基或磺酰基;Ar是可选地取代的苯基、吡啶基、嘧啶基、噻吩基、呋喃基、噻唑基、恶唑基、噻二唑基或恶二唑基;Q.sup.2是公式II和III的组中选择的:##STR1##,其中R.sup.1是氢、(2-5C)烷酰或可选地取代的苯甲酰;R.sup.2是(1-4C)烷基;R.sup.3是氢或(1-4C)烷基;或者R.sup.2和R.sup.3连接形成一个亚甲基、乙烯基、亚乙基或三亚甲基组;或其药物可接受的盐;其制备过程;包含它们的药物组合物以及它们作为5-脂氧合酶抑制剂的使用。